Globus Medical (GMED) Q3 2026 Earnings Call Transcript

Globus Medical reported Q3 2026 revenue of $763.7 million, down 0.7% year over year, and cut full-year revenue guidance to $3.09 billion from $3.18–$3.22 billion, citing Nevro weakness and delayed U.S. Spine launches. It reaffirmed non-GAAP EPS guidance of $4.95–$5.05; quarterly non-GAAP EPS was $1.23, while free cash flow reached a record $224.8 million. The board also authorized an additional $500 million share-repurchase program.

Analysis

GMED’s key issue is not near-term EPS resilience but whether revenue growth can reaccelerate without sacrificing the margin gains supporting it. The reduced revenue outlook and implied weak Q4 make 2027 launch execution more consequential: SCRIPT, EIQ and the XLIF system are being asked to offset both delayed Spine contribution and Nevro’s still-unproven recovery. That creates a risk of multiple compression if launch uptake is merely adequate rather than incremental to the existing business.

A second-order read-through is that higher robot deployments do not immediately equal higher-quality growth. More rentals and leases can expand placements and future implant pull-through, but defer capital revenue and make utilization, service economics and procedure conversion the better indicators than unit deployments alone. Watch those metrics alongside Nevro trial volumes; hiring progress is not evidence of demand recovery.

Margins and cash generation provide a buffer, but there is a potential trade-off: management expects higher R&D investment while pursuing new platforms and markets. If revenue remains soft, that investment could temper EPS leverage and buyback support. The FDA warning-letter closure removes a discrete regulatory overhang, but does not resolve execution risk.

Contrarian view: the current slowdown may be more company-specific than market-wide, which leaves room for recovery if launches ship reliably and new reps ramp. But that upside is conditional, not yet demonstrated. Over the next 1–3 months, Q4 performance and launch readiness matter; over 6–18 months, implant pull-through, Nevro stabilization and returns on cranial/digital investment determine whether growth broadens.

Key Decisions for Investors

• Avoid adding to GMED solely on EPS growth or buyback activity; wait for evidence that product availability and U.S. Spine growth are recovering. Reassess after the next earnings update.
• For existing exposure, use a neutral-to-cautious stance rather than extrapolating management’s 2027 growth ambitions. The thesis improves if launch timing holds and U.S. Spine growth accelerates; it weakens if further launch delays or another guidance reduction occur.
• Track Enabling Technologies through utilization, service revenue and implant pull-through—not deployments alone. If placements rise but recurring revenue and related implant demand do not follow, treat the adoption signal as lower quality.
• Treat Nevro as a watch item, not a recovery trade: require stabilization in sequential revenue and improvement in trial volumes before underwriting a rebound. A failure to improve into 2027 would undermine the consolidated growth case.